Can novel delivery help Zynerba steal a march on cannabis giant GW?

If it were ever doubted that cannabis-based therapies would one day occupy space in certain specialists’ armamentaria, that time has now certainly passed.

Asked whether a failure to take such therapies seriously had led to institutional resistance, Zynerba Pharmaceuticals (Nasdaq :ZYNE) chief executive Armando Anido tells The Pharma Letter: "If we had tried to do this five or six years ago, we would have seen more of that.”

He adds: “I give GW some credit because they've been at it for more than twenty years, and they blazed a path in this area. By showing data that the drug works, it helps get investors comfortable that it’s not mumbo-jumbo medicine."